{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:58Z","timestamp":1794315418578,"version":"4.9.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Efficacy and Mechanism Evaluation"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Whilst biologic therapy is used for Beh\u00e7et\u2019s syndrome of all subtypes refractory to first-line immunomodulation, there has been an absence of high-quality evidence and no predictive biomarkers to optimally inform choice. BIO-BEH\u00c7ET\u2019S was a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Beh\u00e7et\u2019s.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a Bayesian-designed, pragmatic, standard of care, two-arm, parallel head-to-head trial at four UK centres. Patients with active disease were randomized to infliximab or IFN-\u03b12a, and received follow-up with symptom-directed examination at weeks 12 and 24. The primary outcome was the Beh\u00e7et\u2019s Disease Activity Index (BDAI) at 12\u2009weeks. Secondary outcomes included BDAI at 24\u2009weeks and significant improvement in individual organ systems, including ocular symptoms, oral and genital ulcers, arthritis pain, quality of life, disease activity and steroid use. Biomarkers were also investigated but are reported elsewhere.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-nine patients were recruited. Both treatments were equally effective, with a mean difference of 0.13 in BDAI (80% confidence interval: \u20130.19, 0.46). No significant differences were observed for secondary outcomes, though there were clinically significant within-group reductions for each over time. A modest steroid-sparing effect was observed, with complete cessation of steroids in 20% and 44% of those randomized to infliximab and IFN-\u03b12a, respectively. There was a trend for minor benefit in favour of infliximab in terms of tolerability and persistence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this first reported, high-quality, head-to-head trial of two biologics in Beh\u00e7et\u2019s, both infliximab and IFN-\u03b12a showed comparable short-term clinical efficacy and safety in refractory active disease of all subtypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>EudraCT: 2014\u2013005390-36; ISRCTN: ISRCTN49793874<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae585","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T18:00:51Z","timestamp":1729533651000},"page":"2882-2891","source":"Crossref","is-referenced-by-count":20,"title":["Infliximab <i>vs<\/i> interferon-\u03b1 in the treatment of Beh\u00e7et\u2019s syndrome: clinical data from the BIO-BEH\u00c7ET\u2019S randomized controlled trial"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-6211","authenticated-orcid":false,"given":"Robert J","family":"Moots","sequence":"first","affiliation":[{"name":"Department of Academic Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Aintree University Hospital , Liverpool,","place":["UK"]},{"name":"Faculty of Health, Social Care and Medicine, Edge Hill University , Ormskirk,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-1973","authenticated-orcid":false,"given":"Farida","family":"Fortune","sequence":"additional","affiliation":[{"name":"Institute of Dentistry, Queen Mary University of London , London,","place":["UK"]},{"name":"Barts Health NHS Trust, The London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-5088","authenticated-orcid":false,"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-7596","authenticated-orcid":false,"given":"Tony","family":"Thornburn","sequence":"additional","affiliation":[{"name":"Beh\u00e7et\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-624X","authenticated-orcid":false,"given":"Ann","family":"Morgan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-4282","authenticated-orcid":false,"given":"Daniel F","family":"Carr","sequence":"additional","affiliation":[{"name":"Institute of Systems, Molecular and Integrated Biology, University of Liverpool , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-3795","authenticated-orcid":false,"given":"Philip I","family":"Murray","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-0509","authenticated-orcid":false,"given":"Graham R","family":"Wallace","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-0760","authenticated-orcid":false,"given":"Deva","family":"Situnayake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sandwell and West Birmingham Hospitals , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2025050316124881000_keae585-B1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/rheumatology\/38.12.1171","article-title":"Behc\u00e7et\u2019s syndrome","volume":"38","author":"Barnes","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316124881000_keae585-B3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"2025050316124881000_keae585-B4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3899\/jrheum081008","article-title":"13th International Conference on Beh\u00e7et\u2019s Disease, May 24-27, 2008, P\u00f6rtschach am W\u00f6rthersee, Austria","volume":"36","author":"Dejaco","year":"2009","journal-title":"J Rheumatol"},{"key":"2025050316124881000_keae585-B5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/pgmj.68.801.566","article-title":"Beh\u00e7et\u2019s syndrome in Scotland","volume":"68","author":"Jankowski","year":"1992","journal-title":"Postgrad Med J"},{"key":"2025050316124881000_keae585-B6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/ard.36.6.491","article-title":"Behcet\u2019s syndrome in 32 patients in Yorkshire","volume":"36","author":"Chamberlain","year":"1977","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B7","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/rheumatology\/keaa010","article-title":"Epidemiology, morbidity and mortality in Beh\u00e7et\u2019s disease: a cohort study using The Health Improvement Network (THIN)","volume":"59","author":"Thomas","year":"2020","journal-title":"Rheumatology"},{"key":"2025050316124881000_keae585-B8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.revmed.2013.12.005","article-title":"\u00c9pid\u00e9miologie de la maladie de Beh\u00e7et","volume":"35","author":"Mahr","year":"2014","journal-title":"La Re M\u00e9d Int"},{"key":"2025050316124881000_keae585-B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/rheumatology\/kew486","article-title":"Exploring the variability in Beh\u00e7et\u2019s disease prevalence: a meta-analytical approach","volume":"57","author":"Mahr","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316124881000_keae585-B10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1136\/annrheumdis-2015-209059","article-title":"A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Beh\u00e7et\u2019s disease in HLA-B51 carriers","volume":"75","author":"*Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Beh\u00e7et\u2019s disease: a comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimm"},{"key":"2025050316124881000_keae585-B12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ng.3786","article-title":"Dense genotyping of immune-related loci implicates host responses to microbial exposure in Beh\u00e7et\u2019s disease susceptibility","volume":"49","author":"Takeuchi","year":"2017","journal-title":"Nat Genet"},{"key":"2025050316124881000_keae585-B13","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3390\/ijms21093072","article-title":"Beh\u00e7et\u2019s Disease, and the Role of TNF-\u03b1 and TNF-\u03b1 Blockers","volume":"21","author":"van der Houwen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025050316124881000_keae585-B14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316124881000_keae585-B15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"2025050316124881000_keae585-B16","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","article-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa","volume":"134","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"key":"2025050316124881000_keae585-B17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","article-title":"Interferon therapy in rheumatic diseases: state-of-the-art 2010","volume":"22","author":"Kotter","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"2025050316124881000_keae585-B18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/0-306-48382-3_104","article-title":"Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Beh\u00e7et\u2019s disease with sight-threatening retinal vasculitis","volume":"528","author":"Kotter","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"2025050316124881000_keae585-B19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"2025050316124881000_keae585-B20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the treatment results for Beh\u00e7et uveitis in patients treated with infliximab and interferon","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"2025050316124881000_keae585-B21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316124881000_keae585-B22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B23","author":"Beh\u00e7et\u2019s syndrome centres of excellent website","year":"2023"},{"key":"2025050316124881000_keae585-B24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/acr.24511","article-title":"The OMERACT core set of domains for outcome measures in Beh\u00e7et syndrome","volume":"74","author":"Hatemi","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050316124881000_keae585-B25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","article-title":"Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Beh\u00e7et\u2019s Uveitis: customizing Therapy according to the Clinical Features","volume":"30","author":"De Simone","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"2025050316124881000_keae585-B26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the treatment results for Beh\u00e7et uveitis in patients treated with infliximab and interferon","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"2025050316124881000_keae585-B27","doi-asserted-by":"crossref","first-page":"912906","DOI":"10.3389\/fphar.2022.912906","article-title":"Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with beh\u00e7et\u2019s disease: a systematic review of controlled trials","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025050316124881000_keae585-B28","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et\u2019s disease treated with interferon-alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"key":"2025050316124881000_keae585-B29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1755-3768.2011.02348.x","article-title":"Light on the Horizon: biologicals in Beh\u00e7et Uveitis","volume":"91","author":"Hazirolan","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"2025050316124881000_keae585-B30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"2025050316124881000_keae585-B31","doi-asserted-by":"crossref","first-page":"837.e1","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"2025050316124881000_keae585-B32","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025050316124881000_keae585-B33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JEP.S265645","article-title":"Experimental therapeutic solutions for Behcet\u2019s disease","volume":"13","author":"Bozca","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"2025050316124881000_keae585-B34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with Beh\u00e7et\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: a multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025050316124881000_keae585-B36","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025050316124881000_keae585-B37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316124881000_keae585-B38","first-page":"S0190","article-title":"Efficacy and safety of ustekinumab in Beh\u00e7et disease: results from the prospective phase 2 STELABEC trial","author":"London","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025050316124881000_keae585-B39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316124881000_keae585-B40","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"2025050316124881000_keae585-B41","first-page":"188","article-title":"Different phenotypes identified for Beh\u00e7et syndrome","volume":"17","author":"McHugh","year":"2021","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae585\/61007818\/keae585.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2882\/61007818\/keae585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2882\/61007818\/keae585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:04Z","timestamp":1746303184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2882\/7829156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,21]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae585","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,21]]}}}